Key stats
Market capitalization
109.611MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.07USD
About Bioventus Inc
ISIN
US09075A1088
Sector
Health Technology
Industry
Medical Specialties
Website
bioventus.com
CEO
Kenneth Michael Reali
Headquarters
Durham
Employees
1.2K
Founded
2011
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
$BVS: Bioventus is a $45 TargetI believe the price target for Bioventus can easily be $45. It is a new IPO for a company w/ 700+ employees, disruptive orthobiologics and surgical methods, and high growth potential. Support just needs to pickup. That said, please do your own due diligence and invest at your own risk. Everything I
$BVS is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Bioventus is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing process.
The share price is rising and gonna cont
See all ideas
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0